Study on the Safety of Neladenoson Bialanate, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Dug Given as a Single Oral Dose of 10 mg Immediate Release Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight

Exclusion Criteria

• •An anatomical abnormality of the gut (e.g. gut surgery, continent ileostomy) that could affect the retention times of the drug in the stomach/gut adversely
• •Gastric vagotomy or other condition that might adversely affect the gastric pH level
• •Pancreatic dysfunction/insufficiency
• •Febrile illness within 1 week prior to admission to study center
• •Use of the following co-medications
• •From 2 weeks before administration until end of follow-up:
• •Cytochrome P450 (CYP)3A4 inhibitors (Of note: grapefruit is a strong CYP3A4 inhibitor)
• •CYP3A4 inducers
• •CYP2C8 inhibitors (Of note: clopidogrel is a strong CYP2C8 inhibitor)
• •Theophylline
• •On the day of dosing with neladenoson bialanate:
• •Drugs that undergo significant systemic metabolism over gut wall uridine diphosphate-glucuronosyltransferase 1A1 (UGT1A1) substrates (e.g. irinotecan)
• •Major breast cancer resistance protein (BCRP) substrates
• •Regular daily consumption of more than 1 L - Plasmapheresis within 4 weeks before study drug administration
• •Therapies (e.g. physiotherapy, acupuncture, etc.) within 1 week before study drug administration
• •History of relevant and not cured cardiac rhythm disorders (i.e. Wolff-Parkinson-White syndrome, intermittent second- or third-degree AV block)
• •Positive urine drug screening
• •Subjects tested to be positive for hepatitis B surface antigen (HBsAg) or hepatitis C virus